Polo-like kinase 1 (Plk1), the best characterized member of the mammalian polo-like kinase family, is well regulated throughout the cell cycle at the protein expression level. Moreover, it is known ...

Cyclacel Pharmaceuticals announced the publication of a study demonstrating that the DNAJ-PKAc fusion oncoprotein, which drives the progression of fibrolamellar hepatocellular carcinoma (FLC), can ...

Polo-like kinases (Plks) are a family of evolutionarily conserved serine/threonine kinases, which have an N-terminal catalytic kinase domain and highly conserved C-terminal sequences termed the ...

Researchers at VCU Massey Cancer Center have uncovered a novel function of the gene PLK1 (polo-like kinase 1) that helps prostate cancer cells metastasize (spread) to other parts of the body. This ...

A gene that has for decades been considered a tumor promoter, the PLK1 gene, can also perform the exact opposite function: halting the development of cancer. The role of PLK1 as a target for powerful ...

Oncotarget published "High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC" which reported that the aim of this study was therefore to define ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Using GeneReader NGS system to identify mutations in BRCA 1/2 genes in matched FFPE and blood samples. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not ...

Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for ...

Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2. This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. This abstract ...

Cardiff Oncology Inc. welcomed Mani Mohindru as interim CEO and simultaneously provided what the company dubbed a “positive” but stock-denting clinical update. The firm rolled out data from the ...